Company: DMAC
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001437749-25-034469
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
See accompanying notes to the condensed consolidated financial statements.

3

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Shareholders’Equity

For the Three Months Ended September 30, 2025 and 2024

(In thousands, except share amounts)

(Unaudited)

                                                                                                                Paid-In       Accumulated Other                              
                                                                                                                                                                             
                                                                                                                Capital       Comprehensive                                  
                                                                                                                                                                             
                                                                                                                              Income (Loss)                                  
  Issuance of common shares upon the vesting and settlement of restricted stock units           3,805           —             —                      —                    —  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Balances at December 31, 2024                                                                 42,818,660      $180,697      $23                    ( 140,002       40,718  
  Issuance of common shares upon the exercise of stock options                                  37,000          94            —                      —                   94  
  Share-based compensation expense                                                              —               867           —                      —                  867  
  Unrealized loss on marketable securities                                                      —               —             ( 18                   —                 ( 18  
  Net loss                                                                                      —               —             —                      ( 7,707        ( 7,707  
  Balances at March 31, 2025                                                                    42,859,465      $181,658      $5                     ( 147,709       33,954  
  Issuance of common shares in settlement of deferred stock units                               142,345         —             —                      —                    —  
  Issuance of common shares upon the vesting and settlement of restricted stock units           3,803           —             —                      —                    —  
  Issuance of common shares upon the exercise of stock options                                  66,875          163           —                      —                  163  
  Share-based compensation expense                                                              —               771           —                      —                  771  
  Unrealized loss on marketable securities                                                      —               —             ( 19                   —                 ( 19  
  Net loss                                                                                      —               —             —                      ( 7,699        ( 7,699  
  Balances at June 30, 2025                                                                     43,072,488      $182,592      $( 14                  ( 155,408       27,170  
  Issuance of common shares under